NASDAQ:RARX - Ra Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.00 -0.50 (-2.44 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$20.00
Today's Range$19.74 - $20.67
52-Week Range$4.78 - $23.90
Volume201,497 shs
Average Volume501,502 shs
Market Capitalization$664.16 million
P/E Ratio-8.30
Dividend YieldN/A
Beta0.82
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.93 million
Book Value$3.06 per share

Profitability

Net Income$-54,430,000.00

Miscellaneous

Employees63
Market Cap$664.16 million
OptionableOptionable

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) released its earnings results on Wednesday, November, 7th. The company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.02. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

5 equities research analysts have issued 1 year target prices for Ra Pharmaceuticals' shares. Their forecasts range from $25.00 to $40.00. On average, they expect Ra Pharmaceuticals' share price to reach $32.40 in the next year. This suggests a possible upside of 62.0% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Media stories about RARX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a increase in short interest in December. As of December 14th, there was short interest totalling 1,240,960 shares, an increase of 31.3% from the November 30th total of 945,135 shares. Based on an average daily trading volume, of 1,157,071 shares, the short-interest ratio is currently 1.1 days. Approximately 6.1% of the company's shares are sold short. View Ra Pharmaceuticals' Current Options Chain.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 60)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 54)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 41)
  • Dr. Simon Read, Chief Scientific Officer (Age 47)
  • Mr. Alonso Ricardo, Sr. VP of R&D

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (18.95%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which major investors are buying Ra Pharmaceuticals stock?

RARX stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC and Meeder Asset Management Inc.. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $20.00.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $664.16 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://www.rapharma.com.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel